Neutrophil Extracellular Traps in Different Forms of Systemic Sclerosis

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorCHU de Reims

About this trial

Systemic SClerosis (SSC) is a systemic disease characterized by limited or diffuse cutaneous sclerosis, microangiopathy, overproduction of autoantibodies and variable organ damage due to vasculopathy and/or fibrosis. The loss of self-tolerance is believed to be caused by the dysregulation of both innate and adaptive immune systems and may involve Reactive Oxygen Species (ROS).

Neutrophils are potent producers of ROS and may play a role in endothelial cells and fibrobasts dysfunction, as in autoantibodies generation. However, their role in SSC pathogenesis remains to be determined. Recent studies discovered abnormal regulation of Neutrophil Extracellular Traps (NETs) in other auto-immune diseases such as Systemic Lupus Erythematosus (SLE). NETs are web-like structures composed of chromatin backbones and granular molecules. They are released by activated neutrophils through a process called "NETosis". Nets were first described in 2004 as a novel host defense mechanism to trap and kill foreign pathogens. Recent evidence shows that NETs also participate in the pathogenesis of a variety of inflammatory and autoimmune diseases, including SLE.

The investigators recently highlighted this phenomenon in SSc, especially in patients with vascular complications and/or at a early stage of the disease. The investigators will now explore the factors implicated in this dysregulation of NETosis in SSc.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Patients with systemic sclerosis (ACR-EULAR Criteria)

Patients taking care of in internal medicine or in dermatology department's of the university hospital of Reims

Patients consenting to participate to the study

Patients enrolled in the national healthcare insurance program

Disqualifiers

Patients/Healthy volunteers under 18 years old

Patients/Healthy volunteers protected by the law

Patients/Healthy volunteers not consenting to participate to the study after information

Patients with inflammatory pathology or infectious acute intercurrent pathology in the last 15 days before inclusion

Trial population

Group 1 : Adult with SSc Group 2 : Adult with other connective tissue disease Group 3 : Healthy adult volunteer

Trial design

Design model

Other

Time perspective

Prospective

Treatments tested in this trial

  • Blood sample

    Other intervention

    Blood sample to quantify and qualify NETosis in vivo and ex vivo after different stimulations.

Treatment groups

260 Participants
are divided into 3 treatment groups
Group A: Adult with SSc1 intervention
Group B: Other connective tissue disease1 intervention
Group C: Control1 intervention

Trial outcomes

Primary outcomes

1

Quantification of Neutrophil Extracellular Traps (NETs) generated after stimulation of neutrophils in vitro by serum from SSC, SLE and healthy controls.

Comparative analysis of the quantity of Neutrophil Extracellular Traps (NETs) generated after stimulation of neutrophils in vitro by serum from SSC, other connective tissue diseases and healthy controls. Neutrophils from SSC, other connective tissue diseases and healthy subjects will be used.

Time frame
Day 0

Secondary outcomes

1

Analysis of the composition of Neutrophil Extracellular Traps (NETs)

Comparative analysis of the composition of Neutrophil Extracellular Traps (NETs) generated after stimulation of neutrophils in vitro by serum from SSC, other connective tissue diseases and healthy controls. Neutrophils from SSC, other connective tissue diseases and healthy subjects will be used.

Time frame
Day 0
2

Analysis of the cytokines influencing Neutrophil Extracellular Traps NETs production in vitro

Comparative analysis of the quantity of Neutrophil Extracellular Traps (NETs) generated after stimulation of neutrophils from SSC patients in vitro by differents cytokines

Time frame
Day 0

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.